TABLE 4

Baseline, Mid-Therapy, and Posttherapy Tumor Imaging Results of Specific Tracer Parameters in Soft-Tissue Sarcoma Patients

	Before therapy				During therapy		After therapy
Patient no.	Thymidine flux^*	Verapamil^†	FMISO^‡	¹⁸F-FDG^¶	Thymidine flux^*	FMISO^‡	Thymidine flux^*	Verapamil^†	FMISO^‡	¹⁸F-FDG^¶
1	0.0001	0.403	2.7	3.8	—	—	—	—	—	—
2	0.052	0.401	35.0	9.2	0.016	21.3	0.016	0.260	11.4	4.8
3	0.075	0.676	9.9	3.7	0.008	64.3	—	—	—	4.6
4	0.147	0.659	23.1	35	0.056	17.7	—	—	—	>50
5	0.091	0.888	85.5	11.9	0.018	4.6	0.021	0.230	5.8	2.9
6	0.055	0.490	47.0	6.6	0.019	19.5	0.034	0.251	15.0	—
7	0.126	0.700	58.3	—	0.084	86.3	0.052	0.275	36.1	2.5
8	0.043	0.318	0.6	8.8	0.017	35.5	0.023	0.293	31.2	6.1
9	0.021	0.732	1.9	3.7	0.009	7.1	—	—	—	2.9
10	0.031	0.382	6.8	6.9	0.016	—	—	—	—	—

↵* Flux = mL/g/min.
↵† Flow normalized transport = K₁/flow.
↵‡ Hypoxic volume = mL.
↵¶ ¹⁸F-FDG uptake expressed as maximum standardized uptake value.